Marc Symons
Professor
Karches Center for Oncology Research
The Feinstein Institute For Medical Research
United States of America
Biography
Dr. Symons obtained a PhD in biophysics in 1980 from the Brussels Free University, Belgium. After postdoctoral training at the Weizmann Institute, Israel, and the University of California at San Francisco, he started his independent career at Onyx Pharmaceuticals, a startup biotech company in the Bay Area, where he discovered the roles of the Rho family GTPases Rac1, Cdc42 and RhoA in cancer development.
Research Interest
Upon moving back to the academic environment, first at the Picower Institute and subsequently at what is now called The Feinstein Institute for Medical Research, Dr. Symons has focused his research on the molecular mechanisms that are responsible for tumor cell invasion and survival. A major focus of the research is on two malignant brain tumors, glioblastoma and medulloblastoma.
Publications
-
Chuang Y, Tran NL, Rusk N, Nakada N, Berens ME and Symons M. “Role of synaptojanin 2 in glioma cell migration and invasion.†2004, Cancer Res 64, 8271-75.
-
Symons M, Derry JMJ, Karlak B, Jiang S, McCormick F, Francke U and Abo A. “Wiskott-Aldrich Syndrome Protein, a novel effector for the GTPase Cdc42Hs, is implicated in actin polymerization.†1996, Cell 84, 723-34.
-
Qiu R-G, Chen J, Kirn D, McCormick F and Symons M. “An essential role for Rac in Ras transformation.†1995, Nature 374, 457-9.
